Skip to main content
    C

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.67
    -0.19 (-1.93%)

    Market Cap: $387.16M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Contineum Therapeutics, Inc. Class A Common Stock are Prelude Therapeutics (PRLD), Entera Bio (ENTX) and Prothena Corporation (PRTA). By market cap, Contineum Therapeutics, Inc. Class A Common Stock ranks 7th of the 13 companies on this page; Entera Bio (ENTX) is the largest at $541.57M.

    Peer Comparison

    CTNM's revenue growth of 0.0% is above the peer median of -54.4%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Contineum Therapeutics, Inc. Class A Common Stock (CTNM)$387.16MN/AN/A0.0%N/A0.0%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Entera Bio Ltd (ENTX)$541.57MN/AN/A0.0%-8.5%-100.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    CorMedix Inc (CRMD)$370.64M6.3x0.9x15.5%13.9%-47.7%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Tectonic Therapeutic, Inc. (TECX)$413.27MN/AN/A0.0%N/A0.0%0.00%
    Century Therapeutics Inc (IPSC)$299.63MN/AN/A0.0%N/A-100.0%0.00%
    Candel Therapeutics Inc (CADL)$486.37MN/AN/A0.0%-43.5%0.0%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Rezolute Inc (RZLT)$353.54MN/AN/A0.0%N/A0.0%0.00%
    Peer median$388.62M6.3x16.3x0.0%-7.6%-54.4%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Contineum Therapeutics, Inc. Class A Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Entera Bio Ltd (ENTX)
    Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies...
    ENTX competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    CorMedix Inc (CRMD)
    CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious...
    CRMD competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Tectonic Therapeutic, Inc. (TECX)
    Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel...
    TECX competitors
    Century Therapeutics Inc (IPSC)
    Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy...
    IPSC competitors
    Candel Therapeutics Inc (CADL)
    Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform...
    CADL competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Rezolute Inc (RZLT)
    Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States.
    RZLT competitors

    Frequently Asked Questions About CTNM

    Who are Contineum Therapeutics, Inc. Class A Common Stock's main competitors?

    The companies most similar to Contineum Therapeutics, Inc. Class A Common Stock include Prelude Therapeutics (PRLD), Entera Bio (ENTX), Prothena Corporation (PRTA), Lineage Cell Therapeutics (LCTX) and CorMedix (CRMD), listed from the closest match.

    Who is Contineum Therapeutics, Inc. Class A Common Stock's biggest competitor?

    Entera Bio (ENTX) is the largest of the similar companies at $541.57M; Prelude Therapeutics (PRLD) is the closest match by business profile, size, sector and industry.

    How does CTNM stock compare with its competitors?

    CTNM's net margin is 0.0% against a peer median of 0.0%.

    Which of Contineum Therapeutics, Inc. Class A Common Stock's competitors pays a higher dividend?

    Contineum Therapeutics, Inc. Class A Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Contineum Therapeutics, Inc. Class A Common Stock bigger than its competitors?

    No. Contineum Therapeutics, Inc. Class A Common Stock is 7th by market cap among the 13 companies on this page; the largest is Entera Bio (ENTX) at $541.57M.